Sham Mailankody, MBBS
Disclosures
Mailankody reports numerous ties to industry.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
The new treatments that are available are all in the realm of immunotherapies, and we'll start with CAR T-cells or chimeric antigen receptor T cells. The very first CAR T-cell trials for myeloma was just a little over 10 years back; the first patients were treated in 2014. And subsequently, based on Phase II single-arm studies in very late-line patients, these are patients with 4, 5, 6 lines of treatment, both ide-cel and cilta-cel, the two BCMA-targeting CAR-T cells, were initially approved for patients with four or more prior lines of treatment. And again, as I mentioned, these approvals were based on single-arm studies.
